Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide combinations in Multiple Myeloma
NCT03989414Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Sep 2019
- Primary completion
- Nov 2026
- Modality
- Molecular Glues
- Countries
- 9
01
Overview
A Phase 2 trial of mezigdomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Sep 2019; status: active, not recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03989414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989414.